The specific goals of this K24 application are twofold. First, I will further develop a research training program to prepare the next generation of clinical investigators for pharmaco-epidemiologic analyses and improved communication about the safety of drugs used for arthritis and osteoporosis. Over the prior decade seven years, I have mentored 27 different trainees and junior faculty on many projects. This work has been gratifying and productive. This K24 proposal gives me the opportunity to develop a formal program of mentoring with financial support. The mentoring plan to achieve this goal includes detailed descriptions of potential trainees, a multi-faceted program of didactic and project- based education, as well as an evaluation system. Second, I will expand my current patient-oriented research program examining the safety of disease modifying anti-rheumatic drug (DMARD) therapy for rheumatoid arthritis (RA) and developing methods for better communication of potential drug risk. To achieve the second goal, I propose three aims pertaining to new research.
The first aim will focus on improving the methods for studying drug safety among patients with RA when using large health care utilization databases. The methodologic issues include improving algorithms for defining RA, assessing for channeling bias among users of biologic DMARDs, and validating a method for assessing RA severity.
The second aim will estimate the risk of cancer, infection and congestive heart failure (CHF) associated with biologic DMARDs compared with each other and compared with traditional DMARDs. I hypothesize that specific biologic DMARDs will be associated with increased risk of cancer, infection, and CHF. These analyses will focus on both the TNFa antagonists as well as the other emerging biologic therapies, such as abatacept and rituximab. While similar studies have been conducted in the past, they have generally included smaller cohorts of patients with RA than what we have proposed. Moreover, prior studies have not adequately dealt with the potential for channeling bias and for disease severity.
The third aim proposes to survey patients and clinicians regarding their perceptions of DMARD risk and to explores how best to communicate risk. Risk communication is a poorly researched area. Recent high profile drug withdrawals underscore the need for better methods to communicate the potential risks associated with all medications and to place those risks in the proper context. I hypothesize a) that patient's perceptions of risk are associated with their use of specific biologic DMARDs and b) that physicians'perception of risk is much lower than patients'.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24AR055989-05
Application #
8278595
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Witter, James
Project Start
2008-05-08
Project End
2013-06-30
Budget Start
2012-05-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$150,335
Indirect Cost
$11,136
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Yoshida, Kazuki; Hernández-Díaz, Sonia; Solomon, Daniel H et al. (2017) Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology 28:387-395
Lee, Moa P; Lii, Joyce; Jin, Yinzhu et al. (2017) Patterns of Systemic Treatment for Psoriatic Arthritis in the United States: 2004-2015. Arthritis Care Res (Hoboken) :
Feldman, Candace H; Marty, Francisco M; Winkelmayer, Wolfgang C et al. (2017) Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. Arthritis Rheumatol 69:387-397
Paik, Julie M; Kim, Seoyoung C; Feskanich, Diane et al. (2017) Gout and Risk of Fracture in Women: A Prospective Cohort Study. Arthritis Rheumatol 69:422-428
Tedeschi, Sara K; Frits, Michelle; Cui, Jing et al. (2017) Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. Arthritis Care Res (Hoboken) 69:1920-1925
Kim, Seoyoung C; Paik, Julie M; Liu, Jun et al. (2017) Gout and the Risk of Non-vertebral Fracture. J Bone Miner Res 32:230-236
Yoshida, Kazuki; Yu, Zhi; Greendale, Gail A et al. (2017) Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with three-group matching weights. Pharmacoepidemiol Drug Saf :
Yu, Zhi; Lu, Bing; Agosti, Jenifer et al. (2017) Implementation of Treat to Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data from the TRACTION Trial. Arthritis Care Res (Hoboken) :
Choi, Nam-Kyong; Solomon, Daniel H; Tsacogianis, Theodore N et al. (2017) Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res 32:611-617
Lin, Tzu-Chieh; Yoshida, Kazuki; Tedeschi, Sara K et al. (2017) Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis. Arthritis Care Res (Hoboken) :

Showing the most recent 10 out of 146 publications